The Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) drugs in development market research report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) by nine companies/universities/institutes. The top development phase for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) is phase i with three drugs in that stage. The Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline products market are: Alexion Pharmaceuticals, Novartis and Q32 Bio.
The key targets in the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline products market include Complement C3, Complement Factor D, and Complement Factor B.
The key mechanisms of action in the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline product include Complement C3 Inhibitor with two drugs in Phase III. The Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline products market including Small Molecule, and Monoclonal Antibody.
Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) overview
Membranoproliferative glomerulonephritis (MPGN) is a type of glomerulonephritis caused by deposits in the kidney glomerular mesangium and basement membrane (GBM) causing thickening, activating the complement system, and damaging the glomeruli. It is caused by an autoimmune reaction where the immune system attacks healthy cells in kidneys.
For a complete picture of Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
